This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Elisabetta
Bugianesi
Scientific Director, Department of Medical Sciences, University of Torino, Torino, Italy

Dr Bugianesi MD, PhD, is currently Professor of Gastroenterology and Scientific Director of the Dept of Medical Sciences at the University of Turin in Italy. Dr Bugianesi received her MD and her Internal Medicine Residency at the University of Bologna. Her post-graduate training included a PhD fellowship at Case Western Reserve University, Cleveland, USA, from 1995 to 1998 where she became expert in the use of stable isotopes to study in vivo metabolism.

 

Dr Bugianesi is an international acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD) with over 15-years’ experience.  She contributed to the field with work describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease (including the first demonstration of HCC as a complication of NASH), the development of non-invasive markers of fibrosis, and the involvement in several trials for the treatment of NAFLD/NASH. Her contribution to science is testified by over 200 publications, an H Index = 66, N. Citations = 20730 (Scopus).

 

She has been national PI of major EU funded research consortia: Fatty Liver: Inhibition of Progression (FLIP) (2010-2013), ‘EPoS’ Elucidating Pathways of Steatohepatitis (2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (IMI2, 2017-2022). As clinician, she is a practicing Hepatologist based at the GI Division of the University Hospital “Città della Salute e della Scienza of Torino”, Italy. 

Phil Newsome

Phil Newsome

Professor of Hepatology, University of Birmingham Director, Centre for Liver and Gastrointestinal Research Consultant Hepatologist, Liver Unit, Queen Elizabeth Hospital, Birmingham Deputy Director, Birmingham NIHR Biomedical Research Centre (BRC) Directo, Birmingham, United Kingdom


Phil Newsome is Professor of Hepatology, Director of the Centre for Liver and Gastrointestinal Research at the University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital in Birmingham, United Kingdom. Professor Newsome is also the Deputy Director for the Birmingham NIHR Biomedical Research Centre (BRC) and the Director of the Midlands & Wales Advanced Therapy Treatment Centre.

 

Professor Newsome runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD.

 

He has published 198 papers (99 since 2016). Cited 11280 times; h index of >50. Raised >£50M in grant income with £20M active funding.

 

He undertook pivotal studies on community prevalence (J.Hep 2012) and natural history (Gastroenterology 2020) and developed new strategies for determining NAFL severity (Gastro 2020/Lancet GH 2020 – FAST score). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapies in NAFLD published in the Lancet and the NEJM. He is the Co-ordinating Investigator for several global NAFLD studies. He is an editor of a recently published textbook on Liver Transplantation, chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD. He led the recent UK multi-stakeholder guideline group on the management of abnormal liver blood tests and led on NAFLD for the recent EASL Lancet Liver Commission. He recently completed his term as Secretary General (President) of EASL.

 

Professor Newsome’s research portfolio has led to high impact publications throughout, including both original articles (NEJM, PNAS, Gastroenterology, Hepatology, Journal of Hepatology, Gut, American Journal of Transplantation, Annals of Internal Medicine, Lancet, Nature and Nature Comms) and review articles (FASEB, Gastroenterology, Journal of Hepatology). 


Read full bio
Sven Franque

Sven Francque

Chairman, Department of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp, Belgium


Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.

 

He has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression and leading to his PhD in 2011. His research unit continues to study pathophysiological mechanisms of NASH. He is also conducting clinical research and his unit is partner in several research consortia supported by the European Commission and by the Innovative Medicines Initiative with a focus on NASH pathophysiology, biomarker research and hepatocellular carcinoma. His clinical trial unit participates from the early days of clinical trials in NASH in many clinical trials in the field.

 

Prof. Francque is a scientific committee member involved in the design of several phase 2 and current phase 3 trials in NAFLD and is national and international lead PI of several of these trials. He is author/co-author of over 180 papers in peer-reviewed journals and authored several book chapters on NAFLD. He is editor of JHep Reports, the open-access journal of the European Association for the Study of the Liver. He is senior clinical researcher for the Research Fund of the Flemish government. He is currently chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and senior full professor of medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp. He is scientific coordinator of the Belgian Week of Gastroenterology, the Belgian national research meeting of all scientific societies in gastroenterology and hepatology in Belgium. He coordinated the Belgian guidelines on NAFLD and more recently the EASL and EASO-endorsed NAFLD patient guideline.


Read full bio